Genetic Analysis AS Logo

Genetic Analysis AS

Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.

GEAN | SPGR

Overview

Corporate Details

ISIN(s):
NO0010692130 (+2 more)
LEI:
5493004G3I23R6STCD61
Country:
Norway
Address:
Ulvenveien 80B, 0581 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genetic Analysis AS is a research-driven diagnostics company specializing in the human microbiome market. The company develops and commercializes diagnostic solutions based on its proprietary GA-map® platform, a standardized technology for characterizing the microbiome. Its flagship product is the GA-map® Dysbiosis Test Lx, a CE-marked in-vitro diagnostic test used to identify and characterize gut bacterial imbalances (dysbiosis) in patients with conditions such as IBS and IBD. Genetic Analysis serves laboratory diagnostics, clinical research, and pharmaceutical clients, offering tools for routine testing and the co-development of companion diagnostics to support targeted drug therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genetic Analysis AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genetic Analysis AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genetic Analysis AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America IBO
Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom INDV
INDIVIOR PLC Logo
A pharmaceutical firm developing medicines for addiction and serious mental illnesses.
United States of America INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America IFRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.